T 0325/16 of 10.09.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T032516.20210910
- Date of decision
- 10 September 2021
- Case number
- T 0325/16
- Petition for review of
- -
- Application number
- 10774734.7
- IPC class
- C07H 19/06A61K 31/7068A61P 35/00
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- NOVEL STABLE CRYSTAL OF 1-(2'-CYANO-2'-DEOXY-BETA -D-ARABINOFURANOSYL)CYTOSINE MONOHYDROCHLORIDE
- Applicant name
- Delta-Fly Pharma, Inc.
- Opponent name
- KELTIE LLP
- Board
- 3.3.02
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83Rules of procedure of the Boards of Appeal Art 12(4)
- Keywords
- Amendments
Sufficiency of disclosure
Novelty
Inventive step
Late-filed facts
Late-filed case law - Catchword
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent with the following claims and a description and figures possibly to be adapted:
Claims 1 to 4 of the main request, filed with letter dated 24 March 2017